Anti-cancer therapy based on the repeated administration of oxaliplatin is limited by the development of a disabling neuropathic syndrome with detrimental effects on the patient’s quality of life. The lack of effective pharmacological approaches calls for the identification of innovative therapeutic strategies based on new targets. We focused our attention on the imidazoline I1 receptor (I1-R) and in particular on the selective I1-R agonist 2-(1-([1,1′-biphenyl]-2-yl)propan-2-yl)-4,5-dihydro-1H-imidazole) (carbophenyline). The purpose of this work was the preclinical evaluation of the efficacy of carbophenyline on oxaliplatin-induced neuropathic pain in mice. Carbophenyline, acutely per os administered (0.1–10 mg kg−1), induced a dose-dependent anti-hyperalgesic effect that was completely blocked by the pre-treatment with the I1-R antagonist 3 or the I1/α2 receptor antagonist efaroxan, confirming the I1-R-dependent mechanism. Conversely, pre-treatment with the I2-R antagonist BU224 did not block the anti-nociceptive effect evoked by carbophenyline. Repeated oral administrations of carbophenyline (1 mg kg−1) for 14 days, starting from the first day of oxaliplatin injection, counteracted the development of neuropathic pain in all behavioral tests (cold plate, Von Frey, and paw pressure tests) carried out 24 h after the last carbophenyline treatment on days 7 and 14. In the dorsal horn of the spinal cord, carbophenyline significantly decreased the oxaliplatin-induced astrocyte activation detected by immunofluorescence staining by the specific labelling with GFAP antibody. In conclusion, carbophenyline showed anti-neuropathic properties both after acute and chronic treatment with preventive effect against oxaliplatin-induced astrocyte activation in the spinal cord. Therefore, I1-R agonists emerge as a new class of candidates for the management of oxaliplatin-induced neuropathic pain.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
International Association for the Study of Pain. IASP Taxonomy. Pain terms. Neuropathic pain. Updated 2017. www.iasp-pain.org/Taxonomy#Neuropathicpain
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22:1999–2007.
Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.
Kiernan MC. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer. 2007;43:2631-2633.
Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-44.
Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicol. 2006;27:992-1002.
Di Cesare Mannelli L, Pacini A, Bonaccini L, Zanardelli M, Mello T, Ghelardini C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain. 2013;14:1585-600.
Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014;261:22-33.
Di Cesare Mannelli L, Pacini A, Matera C, et al. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacol. 2014;79:37-48.
Di Cesare Mannelli L, Marcoli M, Micheli L, et al. Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain mechanism mediated by Pannexin 1. Neuropharmacol. 2015;97:133-41.
Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831.
Hershman DL, Lacchetti C, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2014;10(6):e421-e424.
Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40(7):872-82.
Alemany R, Olmos G, GarciaSevilla JA. Labelling I-2B-imidazoline receptors by [H-3]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn-Schmied. Arch Pharmacol. 1997;356:39-47.
Gentili F, Cardinaletti C, Carrieri A, et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur J Pharmacol. 2006;553:73–81.
Li JX, Thorn DA, Qiu Y, Peng BW, Zhang Y. Antihyperalgesic effects of imidazoline I2 receptor ligands in rat models of inflammatory and neuropathic pain. Br J Pharmacol. 2014;171:1580-90.
Bektas N, Nemutlu D, Arsla R. The imidazoline receptors and ligands in pain modulation. Indian J Pharmacol. 2015;47:472-478.
Thorn DA, Zhang Y, Li JX. Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats. Psychopharmacol. 2017;234:1871-1880.
Nikolic K, Agbaba D. Pharmacophore development and SAR studies of imidazoline receptor ligands. Mini-Rev Med Chem. 2012;12:1542−1555.
Cobos-Puc L, Aguayo-Morales H. Cardiovascular Effects Mediated by Imidazoline Drugs: An Update. Cardiovasc Hematol Disord Drug Targets. 2019;19(2):95-108.
Head GA, Burke SL. I1 imidazoline receptors in cardiovascular regulation: the place of rilmenidine. Am J Hypertens. 2000;13:89S–98S.
Ernsberger P. The I1-imidazoline receptor and its cellular signaling pathways. Ann N Y Acad Sci. 1999;881:35–53.
Musgrave IF, Hughes R. 1999. Novel targets and techniques in imidazoline receptor research. Ann N Y Acad Sci. 1999;881:217–228.
Greney H, Ronde P, Magnier C, et al. Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline. Mol Pharmacol. 2000;57:1142–1151.
Yoro SG, Urosevic D, Fellmann L, Greney H, Bousquet P, Feldman J. G-protein inwardly rectifying potassium channels are involved in the hypotensive effect of I1-imidazoline receptor selective ligands. J Hypertens. 2008;26:1025–1032.
Kim YH, Nam TS, Ahn DS, Chung S. Modulation of N-type Ca(2)(+) currents by moxonidine via imidazoline I(1) receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011;409:645–650.
Harraz OF, El-Gowelli HM, Mohy El-Din MM, Ghazal AR, El-Mas MM. Adenosinergic modulation of the imidazoline I(1)- receptor-dependent hypotensive effect of ethanol in acute renal failure. Food Chem Toxicol. 2012;50:2622–2628.
Gentili F, Bousquet P, Carrieri A, et al. Rational design of the new antihypertensive I1-receptor ligand 2-(2-biphenyl-2-yl-1-methyl-ethyl)-4,5-dihydro-1H-imidazole. Lett Drug Des Discov. 2005;2:571-578.
Del Bello F, Bargelli V, Cifani C, et al. Antagonism/agonism modulation to build novel antihypertensives selectively triggering I1-imidazoline receptor activation. ACS Med Chem Lett. 2015;6:496-501.
Gentili F, Bousquet P, Brasili L, et al. Imidazoline Binding Sites (IBS) profile modulation: key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues. J Med Chem. 2003;46:2169-2176.
Eglen RM, Hudson AL, Kendall DA, et al. “Seeing through a glass darkly”: casting light on imidazoline “I” sites. Trends Pharmacol Sci. 1998;19:381-390.
Hudson AL, Gough R, Tyacke R, et al. Novel selective compounds for the investigation of imidazoline receptors. Ann N Y Acad Sci. 1999;881:81-91.
McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol. 2015;172:3189–3193.
Cavaletti GG, Tredici MG, Petruccioli E, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer. 2001;37:2457-2463.
Micheli L, Di Cesare Mannelli L, Rizzi A, et al. 2015. Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. Eur J Pharmacol. 2015;766:155-62.
Tanabe M, Takasu K, Takeuchi Y, Ono H. Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res. 2008;86(15):3258-64.
Russo R, D'Agostino G, Mattace Raso G, et al. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides. 2012;38(1):81-8.
Baptista-De-Souza D, Di Cesare Mannelli L, Zanardelli M, et al. Serotonergic modulation in neuropathy induced by oxaliplatin: effect on the 5HT2C receptor. Eur J Pharmacol. 2014;735:141-9.
Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147:165–174.
Di Cesare Mannelli L, Micheli L, Maresca M, et al. Anti-neuropathic effects of Rosmarinus officinalis L. terpenoid fraction: relevance of nicotinic receptors. Sci Rep. 2016;6:34832
Cardinaletti C, Mattioli L, Ghelfi F, et al. Might adrenergic α2C-agonists/α2A-antagonists become novel therapeutic tools for pain treatment with Morphine? J Med Chem. 2009;52:7319–7322.
Del Bello F, Diamanti E, Giannella M, et al. Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit antidepressant-like effect. ACS Med Chem Lett. 2012;3:535-539.
Del Bello F, Giannella M, Piergentili A, Quaglia W. The 2-substituted imidazoline ring linked to an aromatic moiety by a biatomic bridge: a bioversatile scaffold. Glob Drugs Therap. 2016;1:1-4.
Giusepponi ME, Cifani C, Micioni Di Bonaventura MV, et al. Combined interactions with I1-, I2-imidazoline binding sites and α2-adrenoceptors to manage opioid addiction. ACS Med Chem Lett. 2016;7:956-961.
Gentili F, Bousquet P, Brasili L, et al. α2-Adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole. J Med Chem. 2002;45:32–40.
Del Bello F, Cilia A, Carrieri A, et al. The versatile 2-substituted imidazoline nucleus as a structural motif of ligands directed to the serotonin 5-HT1A receptor. Chem Med Chem. 2016;11:2287–98.
Di Cesare Mannelli L, Ghelardini C, Micheli L, et al. Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives. Eur J Med Chem. 2017;810:128-133.
Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain. 1995;61:391-9.
Pan HL, Chen SR, Eisenach JC. Role of spinal NO in antiallodynic effect of intrathecal clonidine in neuropathic rats. Anesthesiology. 1998;89:1518-23.
Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Ther. 2002;93(1):1-35.
Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;318:CD010967.
Stone LS, Kitto KF, Eisenach JC, Fairbanks CA, Wilcox GL. ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther. 2007;323:899–906.
Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev. 2020;72:50-79.
Ernsberger P, Shen IH. Membrane localization and guanine nucleotide sensitivity of medullary I1-imidazoline binding sites. Neurochem Int. 1997;30:17–23.
Edwards L, Ernsberger P. The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase. Brain Res. 2003;980:71–79.
Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018;70:315-347.
Coppi E, Cherchi F, Fusco I, et al. Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. Pain. 2019;160:1103-1118.
Tanabe M, Kino Y, Honda M, Ono H. Presynaptic I1-imidazoline receptors reduce GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci. 2006;26:1795–1802.
Dixit MP, Upadhya MA, Taksande B, et al. Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors. J Nat Sci Biol Med. 2018;9:115-120.
Gupta S, Sharma B. Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain Res Bull. 2014;102:57-68.
Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23-36.
Von Hehn CA, Baron R, Woolf CJ. Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms. Neuron. 2012;73(4):638–652.
Jacob A, Hack B, Chiang E, Garcia JG, Quigg RJ, Alexander JJ. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 2010;24(6):1682-8.
Nikolic K, Veljkovic N, Gemovic B, Srdic-Rajic T, Agbaba D. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study. Comb Chem High Throughput Screen. 2013;16:298-319
Sharma V, Peddibhotla S, Tepe JJ. Sensitization of cancer cells to DNA damaging agents by imidazolines. J Am Chem Soc. 2006;128:9137-43.
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–2470.
This research was funded by the Italian Ministry of Instruction, University and Research (MIUR), by the University of Florence and by the University of Camerino (Fondo di Ateneo per la Ricerca 2018).
Required Author Forms
Disclosure forms provided by the authors are available with the online version of this article.
Conflict of Interest
The authors declare that they have no conflict of interest.
Dedicated to Prof. Maria Pigini
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Micheli, L., Di Cesare Mannelli, L., Del Bello, F. et al. The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity. Neurotherapeutics (2020). https://doi.org/10.1007/s13311-020-00873-y
- Imidazoline I1 receptor agonist
- chemotherapy-induced neuropathic pain